Abstract
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the world with approximately 450 new cases yearly in Denmark. The disease is highly heterogeneous, and half of the patients will never require treatment. The standard treatment is chemoimmunotherapy, but highly effective targeted therapies are approved for patients with high-risk disease or relapse as summarised in this review. The Danish CLL guidelines are continuously updated based on results from ongoing clinical trials and international guidelines.
| Translated title of the contribution | Chronic lymphocytic leukaemia |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 183 |
| Issue number | 42 |
| Pages (from-to) | V03210259 |
| ISSN | 0041-5782 |
| Publication status | Published - 18 Oct 2021 |